Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251934
Status:
COMPLETED
Last Update Posted:
2024-02-09
First Post:
2024-02-01
Brief Title:
Real-World Patient Characteristics Treatment Patterns and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Real-World Patient Characteristics Treatment Patterns and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective longitudinal observational study conducted using the Flatiron Health electronic health record EHR-derived database BRAF advanced or metastatic ie stage III or IV melanoma patients treated at oncology practices across the US were identified for potential inclusion All included patients were aged 18 years and required to have a diagnosis of melanoma International Classification of Diseases ICD-9 172x ICD-10 C43 or D03x a pathologic unresectable stage III or IV diagnosis subsequent first-line 1L treatment with either immunotherapy IO nivolumab pembrolizumab ipilimumab nivolumab or targeted therapy TT dafratenib trametinib dabtram on or after 01 January 2014 and evidence of a BRAF-positive result at any point in time
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None